Dec. 3, 2008 A research team led by Mitchell Lazar, MD, PhD, Director of the Institute for Diabetes, Obesity, and Metabolism at the University of Pennsylvania School of Medicine, has discovered a key molecular partnership that coordinates body rhythms and metabolism.
Lazar and his colleagues, including the study’s first author, Penn Veterinary Medicine doctoral student Theresa Alenghat, studied a protein called NCoR that modulates the body’s responses to metabolic hormones. They engineered a mutation into mice that prevents NCoR from working with an enzyme that is normally its partner, HDAC3. These animals showed changes in the expression of clock and metabolic genes, and were leaner, more sensitive to insulin, and on different sleep-wake cycles than controls.
The role of the NCoR-HDAC3 partnership in regulating the body’s internal clock was previously unknown. HDAC3 is an enzyme that affects gene expression by binding to receptors in the cell nucleus to affect genes' activity, but not by directly changing DNA. The findings suggest that HDAC via NCoR controls the body’s internal clock, and therefore metabolism, through this epigenetic change. Their findings are reported in Nature on November 26.
“In the fight against the obesity and diabetes epidemics, disruption of NCoR and its enzyme partner, might be a valuable new weapon,” says Lazar.
Most physiological processes cycle every day and night, and the most well-known of these circadian rhythms is the sleep-wake cycle. Abnormal sleep patterns, such as those of shift-workers, can be risk factors for metabolic disorders such as obesity and diabetes. “These diseases have reached epidemic proportions, so scientists are urgently seeking to understand the connections between biological rhythms and metabolism,” notes Lazar.
The daily rhythm of mice with the disrupted molecular partnership was shortened by almost half an hour. Over time, this added up to a shifted daily rhythm.
The mice were also leaner (not gaining as much weight when put on a high-fat diet), and they were protected from developing resistance to the action of insulin, which is a hallmark of the most common form of diabetes in people. Expression of several metabolic genes was also altered in the engineered mice.
“The molecular partnership regulates hormone action as well as clock genes that coordinate circadian rhythms,” says Lazar. “It’s extraordinary that, despite their abnormal sleep-wake cycle, which might have been predicted to cause metabolic problems, the mice were actually healthier metabolically.
“However this finding doesn’t mean people should start changing their sleep patterns because this is really evidence that there is coordination between metabolism and circadian activities, including sleep,” cautions Lazar. “It’s not that the mice are sleeping less, it’s that their sleep cycle is shifted, when compared to mice maintained on a normal sleep-wake cycle.”
Companies are currently targeting enzymes like HDAC with drugs called histone deacetylase (HDAC) inhibitors. “However there are dozens of HDACs, which do not all have the same molecular target,” says Lazar. “If we target all of them we will get unwanted side effects related to the other HDACs. Our results suggest that HDAC3, and especially its partnership with NCoR, could be a specific target for diabetes and obesity.”
In addition to Lazar and Alenghat, Penn co-authors are Katherine Meyers, Shannon Mullican, Kirstin Leitner, Adetoun Adeniji-Adele, Jacqueline Avila, Maja Bućan, Rex Ahima, and Klaus Kaestner. The National Institute of Diabetes and Digestive and Kidney Diseases provided funding for this research.
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.